Clinical Assessment of Pidogrel® Versus Plavix® (CAPP)

Summary

This study aims to demonstrate non-inferiority of Pidogrel ® compared to Plavix ® in patients with coronary disease: * Primary Outcome Measures: measure of platelet reactivity by VerifyNow assay after 600 mg loading dose or after the last maintenance dose (75 mg). * Secondary Outcome Measures: Time to first occurrence of major cardio-vascular events (MACE). * Safety Criteria: severe bleeding (GUSTO scale).

Timeline

Start

2010-04

Primary completion

2011-06

Completion

2011-07

Drugs

Indications